Arrowhead Pharmaceuticals

YTD

ALL

Trade Arrowhead Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ARWR

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. Its drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC.

CEO

Christopher Richard Anzalone

CEOChristopher Richard Anzalone

Employees

711

Employees711

Headquarters

Pasadena, California

HeadquartersPasadena, California

Founded

1989

Founded1989

Employees

711

Employees711

ARWR Key Statistics

Market cap

6.75B

Market cap6.75B

Price-Earnings ratio

-9.37

Price-Earnings ratio-9.37

Dividend yield

—

Dividend yield—

Average volume

2.59M

Average volume2.59M

High today

$48.29

High today$48.29

Low today

$44.52

Low today$44.52

Open price

$47.68

Open price$47.68

Volume

3.08M

Volume3.08M

52 Week high

$95.49

52 Week high$95.49

52 Week low

$37.06

52 Week low$37.06

Stock Snapshot

Arrowhead Pharmaceuticals(ARWR) stock is priced at $47.78, giving the company a market capitalization of 6.75B. It carries a P/E multiple of -9.37.

During the trading session on 2026-11-14, Arrowhead Pharmaceuticals(ARWR) shares reached a daily high of $48.29 and a low of $44.52. At a current price of $47.78, the stock is +7.3% higher than the low and still -1.1% under the high.

Trading activity shows a volume of 3.08M, compared to an average daily volume of 2.59M.

Over the past 52 weeks, Arrowhead Pharmaceuticals(ARWR) stock has traded between a high of $95.49 and a low of $37.06.

ARWR News

TipRanks 19h

Arrowhead Pharmaceuticals Warns Investors of Zero-Interest Notes With Significant Risk of No Return

Arrowhead Pharmaceuticals, Inc. (ARWR) has disclosed a new risk, in the Debt & Financing category. Arrowhead Pharmaceuticals, Inc. issues Notes that do not bea...

Simply Wall St 2d

Arrowhead Pharmaceuticals Reports Weaker Full Year Results, Is The Stock Now Cheap?

Arrowhead Pharmaceuticals (ARWR) has released its full-year results, drawing investor scrutiny as revenue declined to approximately US$450.82 million, about hal...

Simply Wall St 3d

How Investors May Respond To Arrowhead Pharmaceuticals Positive Heart Conference Data

Arrowhead Pharmaceuticals reported past clinical data at the 2026 American Heart Association meeting showing RNAi drugs plozasiran and ARO-DIMER-PA produced lar...

Analyst ratings

93%

of 15 ratings

Buy

93.3%

Hold

6.7%

Sell

More ARWR News

Simply Wall St 5d

What Do Arrowhead Pharmaceuticals New AHA Trial Results Change?

Arrowhead Pharmaceuticals (NasdaqGS:ARWR) reported new clinical data for plozasiran and ARO-DIMER-PA at the American Heart Association Scientific Sessions. Plo...

People also own

Based on the portfolios of people who own ARWR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.